Format

Send to

Choose Destination
Clin Cancer Res. 2014 May 1;20(9):2244-8. doi: 10.1158/1078-0432.CCR-13-2088. Epub 2014 Mar 18.

New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer.

Author information

1
Authors' Affiliation: Upper Aerodigestive Malignancies Division, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Abstract

Recent discoveries that non-small cell lung cancer (NSCLC) can be divided into molecular subtypes based on the presence or absence of driver mutations have revolutionized the treatment of many patients with advanced disease. However, despite these advances, a majority of patients are still dependent on modestly effective cytotoxic chemotherapy to provide disease control and prolonged survival. In this article, we review the current status of attempts to target the epigenome, heritable modifications of DNA, histones, and chromatin that may act to modulate gene expression independently of DNA coding alterations, in NSCLC and the potential for combinatorial and sequential treatment strategies.

PMID:
24644000
PMCID:
PMC4325981
DOI:
10.1158/1078-0432.CCR-13-2088
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center